Compare FLYW & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLYW | CDNA |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | 2021 | 2007 |
| Metric | FLYW | CDNA |
|---|---|---|
| Price | $17.13 | $54.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 6 |
| Target Price | $16.21 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 1.2M | 1.0M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 450.00 | N/A |
| EPS | 0.03 | ★ 2.13 |
| Revenue | ★ $623,025,000.00 | $48,324,000.00 |
| Revenue This Year | $19.68 | $16.01 |
| Revenue Next Year | $15.25 | $11.31 |
| P/E Ratio | $577.67 | ★ $25.21 |
| Revenue Growth | ★ 26.59 | 18.93 |
| 52 Week Low | $10.55 | $13.95 |
| 52 Week High | $19.73 | $55.16 |
| Indicator | FLYW | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 39.85 | 68.92 |
| Support Level | $17.09 | $45.74 |
| Resistance Level | $19.02 | N/A |
| Average True Range (ATR) | 0.62 | 2.02 |
| MACD | -0.16 | -0.03 |
| Stochastic Oscillator | 15.61 | 81.33 |
Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements, namely a payments platform, a proprietary payment network, and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.